Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...

A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer ...

reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...

BOSTON--(BUSINESS WIRE)--Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). reSET-O, ...

Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care. Sandoz and Pear ...

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc., today announced publication of real-world data evaluating the impact of reSET-O, the first and only FDA-authorized Prescription ...

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, announced that the US Food and Drug Administration (FDA) has granted clearance for ...

HOLZKIRCHEN, December 10, 2018 - Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug ...

(RTTNews) - Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced the US commercial launch of reSET-O for patients with Opioid Use Disorder or OUD. reSET-O, cleared by the US Food ...